NSABP B-55 BIG 6-13

Closed to Accrual & Treatment

Return to Protocol Table

OlympiA: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Principal Investigator

Charles Geyer, MD

Status

Closed to Accrual & Treatment

Date Opened To Accrual

July 03 2014

Date Closed to Accrual

August 29 2019

Disease Site

Breast [BR]

Breast

Phase

III

Developmental Therapeutics

Primary Objective

To assess the effect of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS)

Patient Population

Patients with germline BRCA mutations and HER2-negative primary breast cancer who are at high risk of recurrence and who have completed definitive local treatment and systemic neoadjuvant or adjuvant chemotherapy.

Target Accrual

1800

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Investigator Brochure

Investigator Resources

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.